Diabetogenic agent alloxan is a proteasome inhibitor

Biochem Biophys Res Commun. 2017 Jun 24;488(2):400-406. doi: 10.1016/j.bbrc.2017.05.065. Epub 2017 May 11.

Abstract

Alloxan has been used as a diabetogenic agent to induce diabetes. It selectively induces pancreatic β-cell death. The specific toxicity, however, is not fully understood. In this study, we observed the effect of alloxan on proteasome function. We found that alloxan caused the accumulation of ubiquitinated proteins in NRK cells through the inhibition of the proteolytic activities of the proteasome. Biochemistry experiments with purified 26S and 20S proteasomes revealed that alloxan directly acts on the chymotrypsin- and trypsin-like peptidase activities. These results demonstrate that alloxan is a proteasome inhibitor, which suggests that its specific toxicity toward β-cell is at least in part through proteasome inhibition.

Keywords: Alloxan; Diabetes; Proteasome; β-cell toxicity.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Alloxan / chemistry
  • Alloxan / pharmacology*
  • Animals
  • Cells, Cultured
  • Dose-Response Relationship, Drug
  • HEK293 Cells
  • Humans
  • Proteasome Endopeptidase Complex / metabolism*
  • Proteasome Inhibitors / chemistry
  • Proteasome Inhibitors / pharmacology*
  • Rats
  • Structure-Activity Relationship

Substances

  • Proteasome Inhibitors
  • Alloxan
  • Proteasome Endopeptidase Complex